Gene therapy and control of angiogenesis

Ophthalmology Clinics of North America

Volumn 16, Issue 4, 2003, Pages 575-582

  Francis, Peter J ^a   Stout, J Timothy ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOSTATIN; CHEMOKINE; ENDOSTATIN; HYPOXIA INDUCIBLE FACTOR 1; PIGMENT EPITHELIUM DERIVED FACTOR; THROMBOSPONDIN 1; TRYPTOPHAN; VASCULOTROPIN;

ANGIOGENESIS; CANCER; CAPILLARY PROLIFERATION; CELL ADHESION; CELL PROLIFERATION; DIABETIC RETINOPATHY; EXTRACELLULAR MATRIX; GENE THERAPY; GENE TRANSFER; HUMAN; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PSORIASIS; REGULATORY MECHANISM; RETINA MACULA DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; VASODILATATION;

EID: 0346964478     PISSN: 08961549     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-1549(03)00096-8     Document Type: Review

References (60)

1. Griffoen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev 2000;52:237-68.
2. Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002;13:29-37.
3. Jiang BH, Zheng JZ, Leung SW, et al. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem 1997;272:19253-60.
4. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001;107:43-54.
5. Jewell UR, Kvietikova I, Scheid A, et al. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J 2001;15:1312-4.
6. Gu YZ, Moran SM, Hogenesch JB, et al. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 1998;7:205-13.
7. Caro J. Hypoxia regulation of gene transcription. High Alt Med Biol 2001;2:145-54.
8. Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
9. Plate KH, Warnke PC. Vascular endothelial growth factor. J Neurooncol 1997;35:365-72.
10. Fuh G, Garcia KC, de Vos AM. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J Biol Chem 2000;275:26690-5.
11. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994;269:26988-95.
12. Lu M, Adamis AP. Vascular endothelial growth factor gene regulation and action in diabetic retinopathy. Ophthalmol Clin N Am 2002;15:69-79.
13. Lee CH, Smits PC. Vascular growth factors for coronary angiogenesis. J Interv Cardiol 2002;15:511-8.
14. English D, Brindley DN, Spiegel S, et al. Lipid mediators of angiogenesis and the signalling pathways they initiate. Biochim Biophys Acta 2002;1582:228-39.
15. Liu W, Reinmuth N, Stoeltzing O, et al. Antiangiogenic therapy targeting factors that enhance endothelial cell survival. Semin Oncol 2002;29:96-103.
16. Woolf AS, Yuan HT. Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development. Pediatr Nephrol 2001;16:177-84.
17. Jones N, Iljin K, Dumont DJ, et al. Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol 2001;2:257-67.
18. Li J, Zhang YP, Kirsner RS. Angiogenesis in wound repair: angiogenic growth factors and the extracellular matrix. Microsc Res Tech 2003;60:107-14.
19. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol 2001;33:960-70.
20. Anand-Apte B, Pepper MS, Voest E, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci 1997;38:817-23.
21. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P. Mechanism of thrombin-induced angiogenesis. Biochem Soc Trans 2002;30:173-7.
22. Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J Biol Chem 1999;274:23969-76.
23. Westlin WF. Integrins as targets of angiogenesis inhibition. Cancer J 2001;7(Suppl 3):S139-43.
24. Patarroyo M, Tryggvason K, Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin Cancer Biol 2002;12:197-207.
25. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002;8:918-21.
26. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 2002;8:330-4.
27. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8.
28. Jablonski MM, Tombran-Tink J, Mrazek DA, et al. Pigment epithelium-derived factor supports normal development of photoreceptor neurons and opsin expression after retinal pigment epithelium removal. J Neurosci 2000;20:7149-57.
29. Cayouette M, Smith SB, Becerra SP, et al. Pigment epithelium-derived factor delays the death of photoreceptors in mouse models of inherited retinal degenerations. Neurobiol Dis 1999;6:523-32.
30. Singh VK, Chader GJ, Rodriguez IR. Structural and comparative analysis of the mouse gene for pigment epithelium-derived factor (PEDF). Mol Vis 1998;4:7-11.
31. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57.
32. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001;108:785-91.
33. Cao Y, Cao R, Veitonmaki N. Kringle structures and antiangiogenesis. Curr Med Chem Anti-Canc Agents 2002;2:667-81.
34. Otani A, Slike BM, Dorrell MI, et al. A fragment of human TrpRS as a potent antagonist of ocular angiogenesis. Proc Natl Acad Sci U S A 2002;99:178-83.
35. Bernardini G, Ribatti D, Spinetti G, et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003;273:83-101.
36. Spinetti G, Camarda G, Bernardini G, et al. The chemokine CXCL13 (BCA-1) inhibits FGF-2 effects on endothelial cells. Biochem Biophys Res Commun 2001;289:19-24.
37. Castro MG, Cowen R, Williamson IK, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003;98:71-108.
38. Ciardella AP, Donsoff IM, Guyer DR, et al. Antiangiogenesis agents. Ophthalmol Clin N Am 2002;15:453-8.
39. Gardner TW, Antonetti DA, Barber AJ, et al. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002;47(Suppl 2):S253-62,
40. Husain D, Ambati B, Adamis AP, et al. Mechanisms of age-related macular degeneration. Ophthalmol Clin N Am 2002;15:87-91.
41. Pelzek C, Lim JI. Diabetic macular edema: review and update. Ophthalmol Clin N Am 2002;15:555-63.
42. de Felipe P. Polycistronic viral vectors. Curr Gene Ther 2002;2:355-78.
43. Post DE, Van Meir EG. Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther 2001;8:1801-7.
44. Quinonez R, Sutton RE. Lentiviral vectors for gene delivery into cells. DNA Cell Biol 2002;21:937-51.
45. Elson DA, Thurston G, Huang LE, et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev 2001;15:2520-32.
46. Vincent KA, Feron O, Kelly RA. Harnessing the response to tissue hypoxia: HIF-1 alpha and therapeutic angiogenesis. Trends Cardiovasc Med 2002;12:362-7.
47. Vincent KA, Shyu KG, Luo Y, et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000;102:2255-61.
48. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-8.
49. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-72.
50. Yoshida A, Yoshida S, Khalil AK, et al. Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 1998;39:1097-106.
51. Spranger J, Osterhoff M, Reimann M, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001;50:2641-5.
52. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation ADGVPEDF study of, 11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001;12:2029-32.
53. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-7.
54. Otani A, Kinder K, Ewalt K, et al. Bone marrow-derived stem cells target retinal astrocytes and can promote or inhibit retinal angiogenesis. Nat Med 2002;8:1004-10.
55. Talks KL, Harris AL. Current status of antiangiogenic factors. Br J Haematol 2000;109:477-89.
56. The Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002;22:143-52. 2002.
57. Folkman J, Ingber DE. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 1987;206:374-83.
58. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res 1997;29:354-62.
59. Robinson GS, Ju M, Shih SC, et al. Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development. FASEB J 2001;15:1215-7.
60. Lai YK, Shen WY, Brankov M, et al. Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther 2002;9:804-13.